Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
Dyne Therapeutics director Catherine Stehman-Breen received a new stock option grant as part of her compensation. On June 5, 2026 she was awarded options to purchase 35,152 shares of Dyne Therapeutics common stock at an exercise price of $17.04 per share.
The option vests in full on the earlier of June 5, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as she continues to serve. Following this grant, she holds 35,152 stock options directly under this award, which expire on June 4, 2036.
Dyne Therapeutics director Brian S. Posner reported two insider transactions. He made an open-market purchase of 2,000 shares of common stock at $16.94 per share, bringing his directly held stake to 24,500 shares.
He also received a grant of stock options covering 35,152 shares of common stock with an exercise price of $17.04 per share. According to the disclosure, these options vest in full on the earlier of June 5, 2027 or the date of Dyne Therapeutics’ 2027 annual stockholders’ meeting, subject to his continued service.
Dyne Therapeutics, Inc. reported results from its 2026 annual stockholder meeting. Stockholders elected David Lubner, Brian Posner and Jason Rhodes as Class III directors to serve three-year terms ending at the 2029 annual meeting.
Stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers and ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. They also approved an amendment to increase authorized common shares from 200,000,000 to 400,000,000 and a separate amendment providing for officer exculpation, with both amendments effected by certificates of amendment filed on June 8, 2026.
Dyne Therapeutics, Inc. director Brian S. Posner reported an open-market purchase of Common Stock. On June 3, 2026, he bought 2,500 shares at $17.48 per share. After this transaction, his directly held position increased to 22,500 shares of Dyne Therapeutics common stock.
Dyne Therapeutics announced completion of enrollment in the registrational expansion cohort of its Phase 1/2 ACHIEVE trial of z‑basivarsen for myotonic dystrophy type 1. The cohort includes 71 participants, providing the main data set to support potential regulatory submissions.
The company plans topline data from this cohort in the first quarter of 2027, aiming to use these results, along with multiple ascending dose and long‑term extension data, for a potential Biologics License Application seeking U.S. Accelerated Approval in the third quarter of 2027. Dyne anticipates a potential U.S. launch in the first half of 2028 if Priority Review is granted and approval is received, and it is also pursuing approval pathways outside the U.S.
Dyne Therapeutics director Brian S. Posner bought additional shares of the company. On this Form 4, he reported an open-market purchase of 2,000 shares of Common Stock at a price of $18.21 per share on May 26, 2026. After this transaction, he directly owns 20,000 shares.
Dyne Therapeutics, Inc. director Brian S. Posner reported an open-market purchase of 2,500 shares of Common Stock on May 20, 2026 at $17.12 per share. Following this transaction, he directly owns a total of 18,000 Dyne Therapeutics shares.
Dyne Therapeutics Inc ownership disclosure: Janus Henderson Group plc reports beneficial ownership of 13,647,376 shares of Dyne common stock, representing 8.3% of the class. The filing states the Asset Managers exercise shared voting and shared dispositive power over these shares. The filing is submitted on behalf of Janus Henderson Group plc and describes that the Managed Portfolios hold the securities and have the right to receive dividends and sale proceeds.
T. Rowe Price Investment Management, Inc. amended its Schedule 13G to report beneficial ownership of 30,785,801 shares of Dyne Therapeutics common stock as of 03/31/2026. The filing shows sole voting power of 30,419,012 shares and a 18.7% ownership stake.
The filing is signed by Ellen York, Vice President, on 05/15/2026. The filer includes a statement denying beneficial ownership in the filing language.
Dyne Therapeutics, Inc. Chief Commercial Officer Johanna Friedl-Naderer reported an automatic sale of 228 shares of common stock on May 13, 2026 at a weighted average price of $18.36 per share. The shares were sold solely to cover tax withholding tied to the vesting of restricted stock units under a pre-arranged agreement treated as a binding contract consistent with Rule 10b5-1, meaning it was not a discretionary trade. After the transaction, she holds 154,353 shares in total, including 126,040 unvested restricted stock units.